Latest Legal Developments News

Tesoro Gold has reported a significant 42% increase in its Ternera gold resource alongside a robust scoping study and a $34 million equity raise to accelerate development of its El Zorro project in Chile.

Regis Resources reported a solid September quarter with 90.4koz gold production and a $158 million increase in cash and bullion. Key underground projects at Garden Well Main and Rosemont Stage 3 began ore production, supporting steady FY26 guidance.

29Metals reports a steady copper output but significant zinc production decline due to seismic disruptions at Golden Grove, alongside rising operational costs and ongoing progress at Capricorn Copper.

Carawine Resources Limited’s shares have been suspended from trading following a Federal Court ruling that allows QGold Pty Ltd to compulsorily acquire all remaining shares it does not own.

ASIC has initiated civil proceedings against Fiducian’s subsidiary, alleging misleading statements and compliance failures related to a now-closed investment fund. Fiducian is cooperating but remains tight-lipped as the case unfolds.

Bubs Australia Limited reports a striking turnaround in FY25 with revenue up 29% to $102.5 million and net profit soaring 124% to $5.17 million, driven by strong US and China growth. The company awaits permanent FDA approval, a pivotal factor for its future trajectory.

Mayne Pharma reported a robust 5% revenue increase to $408.1 million and more than doubled its underlying EBITDA to $47 million in FY25, driven by strong Women’s Health sales and strategic acquisitions in Dermatology.

The Federal Court of Australia has dismissed Harvey Norman’s appeal against prior legal declarations, setting the stage for an upcoming penalty hearing that could impact the retailer’s future.

G8 Education Limited reported a 12.4% rise in net profit to $22.5 million for the first half of 2025, navigating lower occupancy and divestments with strategic cost controls and capital management.

NRW Holdings reported a 12.2% revenue increase to $3.27 billion in FY25, offset by a significant impairment linked to OneSteel receivables. The company declared a final fully franked dividend of 9.5 cents per share, underscoring confidence despite challenges.

Telix Pharmaceuticals reported a robust 63% increase in revenue to $390.4 million for the first half of 2025, driven by strong Illuccix sales and the acquisition of RLS Radiopharmacies. Despite this growth, the company recorded a net loss of $2.3 million, reflecting increased investments and finance costs.

Australian Pacific Coal Limited has applied to set aside a statutory demand for over $1 million, a move that unfolds alongside its recent restart of underground mining at the Dartbrook Coal Mine.